Tim Anderson, an analyst from Bank of America Securities, reiterated the Sell rating on Moderna. The associated price target was lowered to $21.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Tim Anderson has given his Sell rating due to a combination of factors affecting Moderna’s financial outlook. The company’s revenue guidance for 2025 has been slightly reduced, reflecting a decrease in expected demand for COVID vaccines. Additionally, while Moderna’s operational expenses were lower than anticipated, the company’s reliance on COVID-related revenues poses a significant risk due to the uncertainty in forecasting future demand.
Furthermore, Anderson expresses skepticism about Moderna’s other research and development initiatives, which are crucial for diversifying its revenue streams away from COVID-related products. Despite some promising developments in their pipeline, the company continues to consume cash at a high rate, which is concerning for its financial health. As a result, Anderson has set a lower price objective for Moderna’s stock, indicating a cautious outlook on its future performance.
Anderson covers the Healthcare sector, focusing on stocks such as Eli Lilly & Co, Biogen, and Johnson & Johnson. According to TipRanks, Anderson has an average return of 22.3% and a 69.67% success rate on recommended stocks.